Press Releases
|
|
 = Add Release to Briefcase |
|
| Mar 10, 2010 |
Infinity's Innovative Hedgehog Pathway Inhibitor Program to be Highlighted at Upcoming Conferences |
|
| |
-- Julian Adams, Ph.D., President of R&D and CSO, to Present at New York City Academy of Sciences' "Hedgehog Pathway in Cancer" Symposium ---- Infinity Scientists Also to Discuss Hedgehog Pathway and Data at Biorbis Cancer Stem Cells Meeting and EMBO Workshop on Hedgehog Signaling --
CAMBRIDGE, Mass., March 10, 2010 (GLOBE NEWSWIRE) -- Infinity ...
|
|
| Mar 2, 2010 |
Infinity to Present at Cowen Health Care Conference |
|
| |
CAMBRIDGE, Mass., March 2, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Gerald E. Quirk, Esq., Vice President Corporate Affairs and General Counsel, will present a company overview at the 30th Annual Cowen Health Care Conference on Tuesday, ...
|
|
| Feb 23, 2010 |
Infinity Announces Presentations at Upcoming Lung Cancer Meeting |
|
| |
CAMBRIDGE, Mass., Feb. 23, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that presentations featuring two of its clinical candidates will be made at the 10th Annual Targeted Therapies of the Treatment of Lung Cancer meeting to be held February 24-...
|
|
| Feb 10, 2010 |
Infinity Initiates Clinical Development of Its Fourth Drug Candidate and Announces 2009 Financial Results |
|
| |
Clinical Investigation Initiated for IPI-940 With Broad Potential in Neuropathic and Inflammatory Pain
Financially Strong With Sufficient Capital to Fund Its Operating Plan Into 2013
CAMBRIDGE, Mass., Feb. 10, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today a...
|
|
| Feb 3, 2010 |
Infinity Announces 2009 Financial Results Conference Call |
|
| |
CAMBRIDGE, Mass., Feb. 3, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that management will host a conference call on Wednesday, February 10, 2010 at 4:30 p.m. EST. In the conference call, management will review recent research and development an...
|
|
| Jan 11, 2010 |
Infinity Announces Key 2010 Objectives |
|
| |
CAMBRIDGE, Mass., Jan. 11, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today provided guidance on its anticipated research and development and business goals for 2010. Infinity opens the year with a diverse pipeline of three drug candidates in clinical developme...
|
|
| Jan 11, 2010 |
Infinity Announces Updated Presentation Time at the J.P. Morgan Healthcare Conference |
|
| |
CAMBRIDGE, Mass., Jan. 11, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced the company has an updated presentation time at the 28th Annual J.P. Morgan Healthcare Conference. Adelene Q. Perkins, President and Chief Executive Officer, will present a co...
|
|
| Jan 7, 2010 |
Infinity Announces Presentations at January Conferences |
|
| |
CAMBRIDGE, Mass., Jan. 7, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that presentations will be made at several upcoming conferences.
* Adelene Q. Perkins, President and Chief Executive Officer,
will present a company overview at...
|
|
| Dec 7, 2009 |
Infinity Names Adelene Q. Perkins Chief Executive Officer |
|
| |
Steven H. Holtzman to Serve as Executive Chair of the Board of
Directors in Accordance With Existing Succession Plan
Transition Strategically Positions Infinity for the Future
CAMBRIDGE, Mass., Dec. 7, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that Adelene Q. Perkins ...
|
|
| Nov 17, 2009 |
Infinity's IPI-504 Named One of Windhover and Campbell Alliance's "Top 10 Projects to Watch" in Oncology |
|
| |
CAMBRIDGE, Mass., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Jeffrey Tong, Ph.D., vice president, corporate and product development, will present an overview of IPI-504 (retaspimycin hydrochloride), the company's intravenous heat s...
|
|
| Nov 16, 2009 |
Adelene Q. Perkins Named "Best Executive" at Annual Stevie(R) Awards Ceremony |
|
| |
CAMBRIDGE, Mass., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Adelene Q. Perkins, president and chief business officer, was named the 2009 "Best Executive: Non-Services Business" in the 6th Annual Stevie Awards for Women in Business...
|
|
| Nov 10, 2009 |
Infinity to Present at Upcoming Conferences |
|
| |
CAMBRIDGE, Mass., Nov. 10, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that management will present a company overview at two upcoming conferences.
* Jeffrey K. Tong, Ph.D., Vice President, Corporate and Product
Development, will prese...
|
|
| Nov 9, 2009 |
Infinity Reports Recent R&D Highlights and Third Quarter 2009 Results |
|
| |
-- Enrollment Open in All of Infinity's Ongoing Hsp90 Chaperone
Inhibitor Studies
-- Infinity Maintains Financial Strength to Advance Its Innovative
Product Pipeline
CAMBRIDGE, Mass., Nov. 9, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company...
|
|
| Nov 2, 2009 |
Infinity Announces Third Quarter 2009 Results Conference Call |
|
| |
CAMBRIDGE, Mass., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that management will host a conference call on Monday, November 9, 2009 at 4:30 p.m. EST. In the conference call, management will review recent research and development and bus...
|
|
| Oct 7, 2009 |
Infinity Announces Appointment of Dr. Thomas J. Lynch to Its Board of Directors |
|
| |
CAMBRIDGE, Mass., Oct. 7, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that Thomas J. Lynch, Jr., M.D., has been appointed to its Board of Directors.
Dr. Lynch is the Director of the Yale Cancer Center and the Physician-in-Chief at Smilow Cance...
|
|
| Sep 2, 2009 |
Infinity to Present At Upcoming Conferences |
|
| |
CAMBRIDGE, Mass., Sept. 2, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that management will present a company overview at several upcoming conferences.
* Steven J. Kafka, Ph.D., vice president, finance, will present at
the Rodman & Re...
|
|
| Aug 5, 2009 |
Infinity Reports Recent R&D Highlights and Second Quarter 2009 Results |
|
| |
CAMBRIDGE, Mass., Aug. 5, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reviewed recent R&D highlights, provided updated 2009 guidance, and announced second quarter 2009 financial results.
"Infinity's recent results illustrate the solid foundation we have...
|
|
| Jul 30, 2009 |
Infinity Announces Second Quarter 2009 Results Conference Call |
|
| |
CAMBRIDGE, Mass., July 30, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that Infinity management will host a conference call on Thursday, August 6, 2009 at 8:30 a.m. EDT. In the conference call, management will review recent research and developme...
|
|
| Jul 23, 2009 |
Infinity Paper On Discovery of Its Novel Hedgehog Inhibitor, IPI-926, Published in Journal of Medicinal Chemistry |
|
| |
-- Paper Features Chemistry and Preclinical Data Leading to
Discovery of IPI-926 - Currently in Phase 1 Development --
-- Publication Follows Recent Paper in Science Demonstrating
Potential of Hedgehog Pathway Inhibition with IPI-926 as a
Promising New Approach in Chemo-Resistant Pancreatic Cancer --
CAMBRIDGE, Mas...
|
|
| Jun 29, 2009 |
Infinity Pharmaceuticals Added to Russell 2000(r) Index |
|
| |
CAMBRIDGE, Mass., June 29, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it was added to the Russell 2000(r) Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 26, 2009. The Russell 200...
|
|
|
For historical Infinity Pharmaceuticals announcements, please contact Monique Allaire.
|
|
